Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + paclitaxel + vorinostat
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of bevacizumab (an anti-angiogenic monoclonal antibody targeting VEGF), paclitaxel (a microtubule-stabilizing chemotherapeutic agent), and vorinostat (a histone deacetylase inhibitor). This regimen has been studied primarily for metastatic breast cancer, where vorinostat induces histone and alpha tubulin acetylation and functionally inhibits Hsp90 in breast cancer cells, potentially enhancing the efficacy of paclitaxel and bevacizumab.
02
Targets
HDAC (HDAC family)HSP90 (Heat shock protein 90 chaperone complex)VEGFA (Vascular endothelial growth factor A)HSP90AA1 (Heat shock protein HSP90-alpha)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + paclitaxel + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + paclitaxel + vorinostat.